ID   K1C17_HUMAN             Reviewed;         432 AA.
AC   Q04695; A5Z1M9; A5Z1N0; A5Z1N1; A5Z1N2; A6NDV6; A6NKQ2; Q6IP98; Q8N1P6;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   28-JUN-2023, entry version 214.
DE   RecName: Full=Keratin, type I cytoskeletal 17;
DE   AltName: Full=39.1;
DE   AltName: Full=Cytokeratin-17;
DE            Short=CK-17;
DE   AltName: Full=Keratin-17;
DE            Short=K17;
GN   Name=KRT17;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RX   PubMed=1281771;
RA   Troyanovsky S.M., Leube R.E., Franke W.W.;
RT   "Characterization of the human gene encoding cytokeratin 17 and its
RT   expression pattern.";
RL   Eur. J. Cell Biol. 59:127-137(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND INDUCTION.
RX   PubMed=1372562; DOI=10.1002/eji.1830220415;
RA   Flohr T., Buwitt U., Bonnekoh B., Decker T., Boettger E.C.;
RT   "Interferon-gamma regulates expression of a novel keratin class I gene.";
RL   Eur. J. Immunol. 22:975-979(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT PC2 ASP-109.
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Cervix, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 85-101, AND VARIANT PC2 ASP-92.
RX   PubMed=7539673; DOI=10.1038/ng0395-273;
RA   McLean W.H.I., Rugg E.L., Lunny D.P., Morley S.M., Lane E.B., Swensson O.,
RA   Dopping-Hepenstal P.J.C., Griffiths W.A.D., Eady R.A.J., Higgins C.,
RA   Navsaria H.A., Leigh I.M., Strachan T., Kunkeler L., Munro C.S.;
RT   "Keratin 16 and keratin 17 mutations cause pachyonychia congenita.";
RL   Nat. Genet. 9:273-278(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 101-117; 152-168; 306-322 AND 331-347.
RA   Shen Z., Chen L., Wang G., Liu Y.-F.;
RL   Submitted (MAY-2007) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=2481679; DOI=10.1242/jcs.93.3.419;
RA   Troyanovsky S.M., Guelstein V.I., Tchipysheva T.A., Krutovskikh V.A.,
RA   Bannikov G.A.;
RT   "Patterns of expression of keratin 17 in human epithelia: dependency on
RT   cell position.";
RL   J. Cell Sci. 93:419-426(1989).
RN   [9]
RP   TISSUE SPECIFICITY.
RX   PubMed=10651700; DOI=10.1046/j.1365-2133.2000.03246.x;
RA   De Berker D., Wojnarowska F., Sviland L., Westgate G.E., Dawber R.P.,
RA   Leigh I.M.;
RT   "Keratin expression in the normal nail unit: markers of regional
RT   differentiation.";
RL   Br. J. Dermatol. 142:89-96(2000).
RN   [10]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=10844551; DOI=10.1046/j.1523-1747.2000.00986.x;
RA   McGowan K.M., Coulombe P.A.;
RT   "Keratin 17 expression in the hard epithelial context of the hair and nail,
RT   and its relevance for the pachyonychia congenita phenotype.";
RL   J. Invest. Dermatol. 114:1101-1107(2000).
RN   [11]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=15795121; DOI=10.1016/j.jdermsci.2005.01.001;
RA   Shen Z., Wang G., Fan J.-Y., Li W., Liu Y.-F.;
RT   "HLA DR B1*04, *07-restricted epitopes on Keratin 17 for autoreactive T
RT   cells in psoriasis.";
RL   J. Dermatol. Sci. 38:25-39(2005).
RN   [12]
RP   INDUCTION.
RX   PubMed=15608502; DOI=10.1159/000081685;
RA   Bockelmann R., Horn T., Gollnick H., Bonnekoh B.;
RT   "Interferon-gamma-dependent in vitro model for the putative keratin 17
RT   autoimmune loop in psoriasis: exploration of pharmaco- and gene-therapeutic
RT   effects.";
RL   Skin Pharmacol. Physiol. 18:42-54(2005).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [14]
RP   FUNCTION, INDUCTION, AND MUTAGENESIS OF ARG-103; GLU-106; ASN-109; ASN-154;
RP   ILE-155; LEU-157; ASP-160; ASN-333; ARG-334; CYS-336 AND LEU-339.
RX   PubMed=16713453; DOI=10.1016/j.jaad.2006.02.033;
RA   Shen Z., Chen L., Liu Y.-F., Gao T.-W., Wang G., Fan X.-L., Fan J.-Y.,
RA   Fan P.-S., Li C.-Y., Liu B., Dang Y.-P., Li C.-X.;
RT   "Altered keratin 17 peptide ligands inhibit in vitro proliferation of
RT   keratinocytes and T cells isolated from patients with psoriasis.";
RL   J. Am. Acad. Dermatol. 54:992-1002(2006).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-32, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13; SER-32 AND SER-39, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-32, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   PHOSPHORYLATION AT SER-44.
RX   PubMed=22006917; DOI=10.1074/jbc.m111.302042;
RA   Pan X., Kane L.A., Van Eyk J.E., Coulombe P.A.;
RT   "Type I keratin 17 protein is phosphorylated on serine 44 by p90 ribosomal
RT   protein S6 kinase 1 (RSK1) in a growth- and stress-dependent fashion.";
RL   J. Biol. Chem. 286:42403-42413(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-12; SER-13; SER-32; SER-39;
RP   THR-110 AND SER-323, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-15; LYS-399 AND LYS-419, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [22]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-15; LYS-399; LYS-400 AND LYS-419,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [23]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-15 AND LYS-399, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [24]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-15; LYS-278; LYS-399; LYS-400 AND
RP   LYS-419, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [25]
RP   VARIANTS PC2 SER-92 AND ASP-98, AND VARIANTS SM HIS-92 AND HIS-94.
RX   PubMed=9008238; DOI=10.1111/1523-1747.ep12335315;
RA   Smith F.J.D., Corden L.D., Rugg E.L., Ratnavel R., Leigh I.M., Moss C.,
RA   Tidman M.J., Hohl D., Huber M., Kunkeler L., Munro C.S., Lane E.B.,
RA   McLean W.H.I.;
RT   "Missense mutations in keratin 17 cause either pachyonychia congenita type
RT   2 or a phenotype resembling steatocystoma multiplex.";
RL   J. Invest. Dermatol. 108:220-223(1997).
RN   [26]
RP   VARIANTS PC2 SER-92 AND CYS-94, AND VARIANT SM CYS-94.
RX   PubMed=9767294; DOI=10.1046/j.1365-2133.1998.02413.x;
RA   Covello S.P., Smith F.J.D., Sillevis Smitt J.H., Paller A.S., Munro C.S.,
RA   Jonkman M.F., Uitto J., McLean W.H.I.;
RT   "Keratin 17 mutations cause either steatocystoma multiplex or pachyonychia
RT   congenita type 2.";
RL   Br. J. Dermatol. 139:475-480(1998).
RN   [27]
RP   VARIANT PC2 THR-88.
RX   PubMed=10571744; DOI=10.1046/j.1523-1747.1999.00762.x;
RA   Celebi J.T., Tanzi E.L., Yao Y.J., Michael E.J., Peacocke M.;
RT   "Mutation report: identification of a germline mutation in keratin 17 in a
RT   family with pachyonychia congenita type 2.";
RL   J. Invest. Dermatol. 113:848-850(1999).
RN   [28]
RP   VARIANTS PC2 94-PRO--TYR-98 DEL; PRO-94 AND GLN-95.
RX   PubMed=11348474; DOI=10.1046/j.1523-1747.2001.01335.x;
RA   Smith F.J.D., Coleman C.M., Bayoumy N.M., Tenconi R., Nelson J., David A.,
RA   McLean W.H.I.;
RT   "Novel keratin 17 mutations in pachyonychia congenita type 2.";
RL   J. Invest. Dermatol. 116:806-808(2001).
RN   [29]
RP   VARIANTS PC2 PRO-95; SER-97 DEL AND PRO-99.
RX   PubMed=11886499; DOI=10.1046/j.0022-202x.2001.01565.x;
RA   Terrinoni A., Smith F.J.D., Didona B., Canzona F., Paradisi M., Huber M.,
RA   Hohl D., David A., Verloes A., Leigh I.M., Munro C.S., Melino G.,
RA   McLean W.H.I.;
RT   "Novel and recurrent mutations in the genes encoding keratins K6a, K16 and
RT   K17 in 13 cases of pachyonychia congenita.";
RL   J. Invest. Dermatol. 117:1391-1396(2001).
RN   [30]
RP   VARIANT PC2 MET-102.
RX   PubMed=11874497; DOI=10.1046/j.0022-202x.2001.01701.x;
RA   Hashiguchi T., Yotsumoto S., Shimada H., Terasaki K., Setoyama M.,
RA   Kobayashi K., Saheki T., Kanzaki T.;
RT   "A novel point mutation in the keratin 17 gene in a Japanese case of
RT   pachyonychia congenita type 2.";
RL   J. Invest. Dermatol. 118:545-547(2002).
RN   [31]
RP   VARIANT PC2 ASP-109.
RX   PubMed=15102078; DOI=10.1111/j.0022-202x.2004.22408.x;
RA   Xiao S.-X., Feng Y.-G., Ren X.-R., Tan S.-S., Li L., Wang J.-M., Shi Y.-Z.;
RT   "A novel mutation in the second half of the keratin 17 1A domain in a large
RT   pedigree with delayed-onset pachyonychia congenita type 2.";
RL   J. Invest. Dermatol. 122:892-895(2004).
RN   [32]
RP   VARIANT PC2 MET-102.
RX   PubMed=15795125; DOI=10.1016/j.jdermsci.2004.12.022;
RA   Uchida T., Inaoki M., Makino E., Fujimoto W.;
RT   "Identification of a recurrent mutation in keratin 17 in a Japanese family
RT   with pachyonychia congenita type 2.";
RL   J. Dermatol. Sci. 38:60-63(2005).
RN   [33]
RP   VARIANTS PC2 SER-92 AND PRO-388.
RX   PubMed=16250206; DOI=10.1111/j.1087-0024.2005.10204.x;
RA   Smith F.J., Liao H., Cassidy A.J., Stewart A., Hamill K.J., Wood P.,
RA   Joval I., van Steensel M.A., Bjoerck E., Callif-Daley F., Pals G.,
RA   Collins P., Leachman S.A., Munro C.S., McLean W.H.;
RT   "The genetic basis of pachyonychia congenita.";
RL   J. Investig. Dermatol. Symp. Proc. 10:21-30(2005).
RN   [34]
RP   VARIANT PC2 THR-88, AND VARIANT SM THR-88.
RX   PubMed=16620218; DOI=10.1111/j.1346-8138.2006.00037.x;
RA   Oh S.-W., Kim M.Y., Lee J.S., Kim S.-C.;
RT   "Keratin 17 mutation in pachyonychia congenita type 2 patient with early
RT   onset steatocystoma multiplex and Hutchinson-like tooth deformity.";
RL   J. Dermatol. 33:161-164(2006).
RN   [35]
RP   VARIANT PC2 SER-92.
RX   PubMed=17719747; DOI=10.1016/j.jdermsci.2007.07.003;
RA   Liao H., Sayers J.M., Wilson N.J., Irvine A.D., Mellerio J.E., Baselga E.,
RA   Bayliss S.J., Uliana V., Fimiani M., Lane E.B., McLean W.H., Leachman S.A.,
RA   Smith F.J.;
RT   "A spectrum of mutations in keratins K6a, K16 and K17 causing pachyonychia
RT   congenita.";
RL   J. Dermatol. Sci. 48:199-205(2007).
RN   [36]
RP   VARIANT PC2 LYS-88.
RX   PubMed=18547302; DOI=10.1111/j.1365-2133.2008.08684.x;
RA   Tsuda T., Ishikawa C., Nakagawa N., Konishi H., Tarutani M., Matsuki M.,
RA   Yamanishi K.;
RT   "A novel point mutation of keratin 17 (KRT17) in a Japanese family with
RT   pachyonychia congenita type 2: an RNA-based genetic analysis using a single
RT   hair bulb.";
RL   Br. J. Dermatol. 159:730-732(2008).
RN   [37]
RP   VARIANTS PC2 SER-92 AND HIS-94.
RX   PubMed=19470054; DOI=10.1111/j.1468-3083.2009.03180.x;
RA   Wang J.F., Lu W.S., Sun L.D., Lv Y.M., Zhou F.S., Fang Q.Y., Tang H.Y.,
RA   Cui Y., Yang S., Zhang X.J.;
RT   "Novel missense mutation of keratin in Chinese family with steatocystoma
RT   multiplex.";
RL   J. Eur. Acad. Dermatol. Venereol. 23:723-724(2009).
RN   [38]
RP   VARIANTS PC2 92-ASN--LEU-99 DEL AND SER-92.
RX   PubMed=21326300; DOI=10.1038/jid.2011.20;
RA   Wilson N.J., Leachman S.A., Hansen C.D., McMullan A.C., Milstone L.M.,
RA   Schwartz M.E., McLean W.H., Hull P.R., Smith F.J.;
RT   "A large mutational study in pachyonychia congenita.";
RL   J. Invest. Dermatol. 131:1018-1024(2011).
RN   [39]
RP   VARIANT PC2 ARG-388.
RX   PubMed=23278621; DOI=10.1111/j.1365-4632.2010.04667.x;
RA   Qiang W., Kaibo W., Tienan L., Guilan Z., Yueyang L., Ting X., Fangji S.;
RT   "A novel mutation of keratin 17 gene in a pedigree with pachyonychia
RT   congenita type 2.";
RL   Int. J. Dermatol. 52:117-119(2013).
RN   [40]
RP   VARIANT PC2 PRO-91.
RX   PubMed=23855588; DOI=10.1111/1346-8138.12212;
RA   Ichimiya M., Yamaguchi M., Nemoto K., Muto M.;
RT   "Novel mutation (p.L91P, c.272T>C) of keratin 17 in a case with
RT   pachyonychia congenita type 2.";
RL   J. Dermatol. 40:757-758(2013).
CC   -!- FUNCTION: Type I keratin involved in the formation and maintenance of
CC       various skin appendages, specifically in determining shape and
CC       orientation of hair (By similarity). Required for the correct growth of
CC       hair follicles, in particular for the persistence of the anagen
CC       (growth) state (By similarity). Modulates the function of TNF-alpha in
CC       the specific context of hair cycling. Regulates protein synthesis and
CC       epithelial cell growth through binding to the adapter protein SFN and
CC       by stimulating Akt/mTOR pathway (By similarity). Involved in tissue
CC       repair. May be a marker of basal cell differentiation in complex
CC       epithelia and therefore indicative of a certain type of epithelial
CC       'stem cells'. Acts as a promoter of epithelial proliferation by acting
CC       a regulator of immune response in skin: promotes Th1/Th17-dominated
CC       immune environment contributing to the development of basaloid skin
CC       tumors (By similarity). May act as an autoantigen in the
CC       immunopathogenesis of psoriasis, with certain peptide regions being a
CC       major target for autoreactive T-cells and hence causing their
CC       proliferation. {ECO:0000250|UniProtKB:Q9QWL7,
CC       ECO:0000269|PubMed:10844551, ECO:0000269|PubMed:15795121,
CC       ECO:0000269|PubMed:16713453}.
CC   -!- SUBUNIT: Heterodimer of a type I and a type II keratin. KRT17
CC       associates with KRT6 isomers (KRT6A or KRT6B). Interacts with TRADD and
CC       SFN (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q04695; Q15834: CCDC85B; NbExp=2; IntAct=EBI-297873, EBI-739674;
CC       Q04695; P26641: EEF1G; NbExp=2; IntAct=EBI-297873, EBI-351467;
CC       Q04695; Q86WT6: TRIM69; NbExp=3; IntAct=EBI-297873, EBI-749955;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q9QWL7}.
CC   -!- TISSUE SPECIFICITY: Expressed in the outer root sheath and medulla
CC       region of hair follicle specifically from eyebrow and beard, digital
CC       pulp, nail matrix and nail bed epithelium, mucosal stratified squamous
CC       epithelia and in basal cells of oral epithelium, palmoplantar epidermis
CC       and sweat and mammary glands. Also expressed in myoepithelium of
CC       prostate, basal layer of urinary bladder, cambial cells of sebaceous
CC       gland and in exocervix (at protein level).
CC       {ECO:0000269|PubMed:10651700, ECO:0000269|PubMed:10844551,
CC       ECO:0000269|PubMed:1281771, ECO:0000269|PubMed:2481679}.
CC   -!- INDUCTION: Induced in damaged or stressed epidermis. Induced by the
CC       cytokines interferon-gamma (IFN-gamma), tumor necrosis factor alpha
CC       (TNF-alpha) and transforming growth factor-alpha (TGF-alpha), and by
CC       the potent NF-kappa B inhibitor compounds Bay 11-7082 and Bay 11-7085.
CC       Down-regulated by the drug Imatinib. {ECO:0000269|PubMed:1372562,
CC       ECO:0000269|PubMed:15608502, ECO:0000269|PubMed:15795121,
CC       ECO:0000269|PubMed:16713453}.
CC   -!- PTM: Phosphorylation at Ser-44 occurs in a growth- and stress-dependent
CC       fashion in skin keratinocytes, it has no effect on filament
CC       organization. {ECO:0000269|PubMed:22006917}.
CC   -!- DISEASE: Pachyonychia congenita 2 (PC2) [MIM:167210]: An autosomal
CC       dominant ectodermal dysplasia characterized by hypertrophic nail
CC       dystrophy resulting in onchyogryposis (thickening and increase in
CC       curvature of the nail), palmoplantar keratoderma and hyperhidrosis,
CC       follicular hyperkeratosis, multiple epidermal cysts, absent/sparse
CC       eyebrow and body hair, and by the presence of natal teeth.
CC       {ECO:0000269|PubMed:10571744, ECO:0000269|PubMed:11348474,
CC       ECO:0000269|PubMed:11874497, ECO:0000269|PubMed:11886499,
CC       ECO:0000269|PubMed:15102078, ECO:0000269|PubMed:15795125,
CC       ECO:0000269|PubMed:16250206, ECO:0000269|PubMed:16620218,
CC       ECO:0000269|PubMed:16625196, ECO:0000269|PubMed:17719747,
CC       ECO:0000269|PubMed:18547302, ECO:0000269|PubMed:19470054,
CC       ECO:0000269|PubMed:21326300, ECO:0000269|PubMed:23278621,
CC       ECO:0000269|PubMed:23855588, ECO:0000269|PubMed:7539673,
CC       ECO:0000269|PubMed:9008238, ECO:0000269|PubMed:9767294}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Steatocystoma multiplex (SM) [MIM:184500]: Disease
CC       characterized by round or oval cystic tumors widely distributed on the
CC       back, anterior trunk, arms, scrotum, and thighs.
CC       {ECO:0000269|PubMed:16620218, ECO:0000269|PubMed:9008238,
CC       ECO:0000269|PubMed:9767294}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=KRT16 and KRT17 are coexpressed only in pathological
CC       situations such as metaplasias and carcinomas of the uterine cervix and
CC       in psoriasis vulgaris.
CC   -!- MISCELLANEOUS: There are two types of cytoskeletal and microfibrillar
CC       keratin: I (acidic; 40-55 kDa) and II (neutral to basic; 56-70 kDa).
CC   -!- SIMILARITY: Belongs to the intermediate filament family.
CC       {ECO:0000255|PROSITE-ProRule:PRU01188}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH72018.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Human Intermediate Filament Mutation Database;
CC       URL="http://www.interfil.org";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Keratin-17 entry;
CC       URL="https://en.wikipedia.org/wiki/Keratin_17";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z19574; CAA79626.1; -; Genomic_DNA.
DR   EMBL; X62571; CAA44451.1; -; mRNA.
DR   EMBL; AK095342; BAC04534.1; -; mRNA.
DR   EMBL; AC022596; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL353997; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000159; AAH00159.2; -; mRNA.
DR   EMBL; BC011901; AAH11901.1; -; mRNA.
DR   EMBL; BC056421; AAH56421.1; -; mRNA.
DR   EMBL; BC072018; AAH72018.1; ALT_FRAME; mRNA.
DR   EMBL; BC072019; AAH72019.1; -; mRNA.
DR   EMBL; S78515; AAB34565.1; -; Genomic_DNA.
DR   EMBL; EF608068; ABQ96595.1; -; mRNA.
DR   EMBL; EF608069; ABQ96596.1; -; mRNA.
DR   EMBL; EF608070; ABQ96597.1; -; mRNA.
DR   EMBL; EF608071; ABQ96598.1; -; mRNA.
DR   CCDS; CCDS11402.1; -.
DR   PIR; S30433; S30433.
DR   RefSeq; NP_000413.1; NM_000422.2.
DR   AlphaFoldDB; Q04695; -.
DR   SMR; Q04695; -.
DR   BioGRID; 110070; 225.
DR   DIP; DIP-33093N; -.
DR   IntAct; Q04695; 41.
DR   MINT; Q04695; -.
DR   STRING; 9606.ENSP00000308452; -.
DR   GlyCosmos; Q04695; 3 sites, 1 glycan.
DR   GlyGen; Q04695; 7 sites, 1 O-linked glycan (7 sites).
DR   iPTMnet; Q04695; -.
DR   MetOSite; Q04695; -.
DR   PhosphoSitePlus; Q04695; -.
DR   SwissPalm; Q04695; -.
DR   BioMuta; KRT17; -.
DR   DMDM; 547751; -.
DR   SWISS-2DPAGE; Q04695; -.
DR   CPTAC; CPTAC-1516; -.
DR   CPTAC; CPTAC-1517; -.
DR   EPD; Q04695; -.
DR   jPOST; Q04695; -.
DR   MassIVE; Q04695; -.
DR   PaxDb; Q04695; -.
DR   PeptideAtlas; Q04695; -.
DR   PRIDE; Q04695; -.
DR   ProteomicsDB; 58264; -.
DR   TopDownProteomics; Q04695; -.
DR   ABCD; Q04695; 2 sequenced antibodies.
DR   Antibodypedia; 6491; 1340 antibodies from 46 providers.
DR   DNASU; 3872; -.
DR   Ensembl; ENST00000311208.13; ENSP00000308452.8; ENSG00000128422.18.
DR   GeneID; 3872; -.
DR   KEGG; hsa:3872; -.
DR   MANE-Select; ENST00000311208.13; ENSP00000308452.8; NM_000422.3; NP_000413.1.
DR   UCSC; uc002hxh.3; human.
DR   AGR; HGNC:6427; -.
DR   CTD; 3872; -.
DR   DisGeNET; 3872; -.
DR   GeneCards; KRT17; -.
DR   GeneReviews; KRT17; -.
DR   HGNC; HGNC:6427; KRT17.
DR   HPA; ENSG00000128422; Tissue enhanced (breast, skin, urinary bladder).
DR   MalaCards; KRT17; -.
DR   MIM; 148069; gene.
DR   MIM; 167210; phenotype.
DR   MIM; 184500; phenotype.
DR   neXtProt; NX_Q04695; -.
DR   OpenTargets; ENSG00000128422; -.
DR   Orphanet; 2309; Pachyonychia congenita.
DR   Orphanet; 841; Sebocystomatosis.
DR   PharmGKB; PA30214; -.
DR   VEuPathDB; HostDB:ENSG00000128422; -.
DR   eggNOG; ENOG502QTM6; Eukaryota.
DR   GeneTree; ENSGT00940000160681; -.
DR   HOGENOM; CLU_012560_8_1_1; -.
DR   InParanoid; Q04695; -.
DR   OMA; GCYSFGS; -.
DR   OrthoDB; 4640531at2759; -.
DR   PhylomeDB; Q04695; -.
DR   TreeFam; TF332742; -.
DR   PathwayCommons; Q04695; -.
DR   Reactome; R-HSA-6805567; Keratinization.
DR   Reactome; R-HSA-6809371; Formation of the cornified envelope.
DR   SignaLink; Q04695; -.
DR   SIGNOR; Q04695; -.
DR   BioGRID-ORCS; 3872; 88 hits in 1107 CRISPR screens.
DR   ChiTaRS; KRT17; human.
DR   GeneWiki; Keratin_17; -.
DR   GenomeRNAi; 3872; -.
DR   Pharos; Q04695; Tbio.
DR   PRO; PR:Q04695; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q04695; protein.
DR   Bgee; ENSG00000128422; Expressed in gingival epithelium and 159 other tissues.
DR   ExpressionAtlas; Q04695; baseline and differential.
DR   Genevisible; Q04695; HS.
DR   GO; GO:0001533; C:cornified envelope; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0045111; C:intermediate filament cytoskeleton; IDA:HPA.
DR   GO; GO:0045095; C:keratin filament; IBA:GO_Central.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0030855; P:epithelial cell differentiation; IBA:GO_Central.
DR   GO; GO:0031069; P:hair follicle morphogenesis; ISS:UniProtKB.
DR   GO; GO:0045109; P:intermediate filament organization; IBA:GO_Central.
DR   GO; GO:0031424; P:keratinization; IEA:Ensembl.
DR   GO; GO:0030307; P:positive regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0051798; P:positive regulation of hair follicle development; IEA:Ensembl.
DR   GO; GO:0045727; P:positive regulation of translation; IEA:Ensembl.
DR   Gene3D; 1.20.5.170; -; 1.
DR   Gene3D; 1.20.5.500; Single helix bin; 1.
DR   Gene3D; 1.20.5.1160; Vasodilator-stimulated phosphoprotein; 1.
DR   InterPro; IPR018039; IF_conserved.
DR   InterPro; IPR039008; IF_rod_dom.
DR   InterPro; IPR002957; Keratin_I.
DR   PANTHER; PTHR23239; INTERMEDIATE FILAMENT; 1.
DR   PANTHER; PTHR23239:SF180; KERATIN, TYPE I CYTOSKELETAL 17; 1.
DR   Pfam; PF00038; Filament; 1.
DR   PRINTS; PR01248; TYPE1KERATIN.
DR   SMART; SM01391; Filament; 1.
DR   SUPFAM; SSF64593; Intermediate filament protein, coiled coil region; 2.
DR   SUPFAM; SSF46579; Prefoldin; 1.
DR   PROSITE; PS00226; IF_ROD_1; 1.
DR   PROSITE; PS51842; IF_ROD_2; 1.
PE   1: Evidence at protein level;
KW   Coiled coil; Cytoplasm; Disease variant; Ectodermal dysplasia;
KW   Intermediate filament; Isopeptide bond; Keratin; Palmoplantar keratoderma;
KW   Phosphoprotein; Reference proteome; Ubl conjugation.
FT   CHAIN           1..432
FT                   /note="Keratin, type I cytoskeletal 17"
FT                   /id="PRO_0000063664"
FT   DOMAIN          84..395
FT                   /note="IF rod"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01188"
FT   REGION          1..83
FT                   /note="Head"
FT   REGION          1..24
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          84..120
FT                   /note="Coil 1A"
FT   REGION          102..116
FT                   /note="Peptide epitope S1; induces T-cell and keratinocyte
FT                   proliferation and IFN-gamma production"
FT   REGION          121..138
FT                   /note="Linker 1"
FT   REGION          139..230
FT                   /note="Coil 1B"
FT   REGION          153..167
FT                   /note="Peptide epitope S2; induces T-cell proliferation and
FT                   IFN-gamma production"
FT   REGION          231..250
FT                   /note="Linker 12"
FT   REGION          251..392
FT                   /note="Coil 2"
FT   REGION          332..346
FT                   /note="Peptide epitope S4; induces T-cell and keratinocyte
FT                   proliferation and IFN-gamma production"
FT   REGION          393..432
FT                   /note="Tail"
FT   MOD_RES         12
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         13
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         25
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61414"
FT   MOD_RES         32
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         39
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         44
FT                   /note="Phosphoserine; by RPS6KA1"
FT                   /evidence="ECO:0000269|PubMed:22006917"
FT   MOD_RES         110
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         279
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6IFV3"
FT   MOD_RES         323
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   CROSSLNK        15
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        15
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        278
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        399
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        399
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        400
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        400
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        419
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        419
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:28112733"
FT   VARIANT         88
FT                   /note="M -> K (in PC2; dbSNP:rs28928898)"
FT                   /evidence="ECO:0000269|PubMed:18547302"
FT                   /id="VAR_072441"
FT   VARIANT         88
FT                   /note="M -> T (in PC2 and SM; dbSNP:rs28928898)"
FT                   /evidence="ECO:0000269|PubMed:10571744,
FT                   ECO:0000269|PubMed:16620218"
FT                   /id="VAR_010512"
FT   VARIANT         91
FT                   /note="L -> P (in PC2)"
FT                   /evidence="ECO:0000269|PubMed:23855588"
FT                   /id="VAR_072442"
FT   VARIANT         92..99
FT                   /note="Missing (in PC2)"
FT                   /evidence="ECO:0000269|PubMed:21326300"
FT                   /id="VAR_072443"
FT   VARIANT         92
FT                   /note="N -> D (in PC2; dbSNP:rs28928896)"
FT                   /evidence="ECO:0000269|PubMed:7539673"
FT                   /id="VAR_003847"
FT   VARIANT         92
FT                   /note="N -> H (in SM; dbSNP:rs28928896)"
FT                   /evidence="ECO:0000269|PubMed:9008238"
FT                   /id="VAR_003848"
FT   VARIANT         92
FT                   /note="N -> S (in PC2; dbSNP:rs59151893)"
FT                   /evidence="ECO:0000269|PubMed:16250206,
FT                   ECO:0000269|PubMed:17719747, ECO:0000269|PubMed:19470054,
FT                   ECO:0000269|PubMed:21326300, ECO:0000269|PubMed:9008238,
FT                   ECO:0000269|PubMed:9767294"
FT                   /id="VAR_003849"
FT   VARIANT         94..98
FT                   /note="Missing (in PC2)"
FT                   /id="VAR_017069"
FT   VARIANT         94
FT                   /note="R -> C (in PC2 and SM; dbSNP:rs58730926)"
FT                   /evidence="ECO:0000269|PubMed:9767294"
FT                   /id="VAR_010513"
FT   VARIANT         94
FT                   /note="R -> H (in SM and PC2; dbSNP:rs28928897)"
FT                   /evidence="ECO:0000269|PubMed:19470054,
FT                   ECO:0000269|PubMed:9008238"
FT                   /id="VAR_003850"
FT   VARIANT         94
FT                   /note="R -> P (in PC2; dbSNP:rs28928897)"
FT                   /evidence="ECO:0000269|PubMed:11348474"
FT                   /id="VAR_017068"
FT   VARIANT         95
FT                   /note="L -> P (in PC2; dbSNP:rs28928899)"
FT                   /evidence="ECO:0000269|PubMed:11886499"
FT                   /id="VAR_017071"
FT   VARIANT         95
FT                   /note="L -> Q (in PC2; dbSNP:rs28928899)"
FT                   /evidence="ECO:0000269|PubMed:11348474"
FT                   /id="VAR_017070"
FT   VARIANT         97
FT                   /note="Missing (in PC2)"
FT                   /evidence="ECO:0000269|PubMed:11886499"
FT                   /id="VAR_017072"
FT   VARIANT         98
FT                   /note="Y -> D (in PC2; dbSNP:rs28933088)"
FT                   /evidence="ECO:0000269|PubMed:9008238"
FT                   /id="VAR_003851"
FT   VARIANT         99
FT                   /note="L -> P (in PC2; dbSNP:rs28933089)"
FT                   /evidence="ECO:0000269|PubMed:11886499"
FT                   /id="VAR_017073"
FT   VARIANT         102
FT                   /note="V -> M (in PC2; dbSNP:rs59977263)"
FT                   /evidence="ECO:0000269|PubMed:11874497,
FT                   ECO:0000269|PubMed:15795125"
FT                   /id="VAR_017074"
FT   VARIANT         109
FT                   /note="N -> D (in PC2; dbSNP:rs267607412)"
FT                   /evidence="ECO:0000269|PubMed:15102078,
FT                   ECO:0000269|PubMed:16625196"
FT                   /id="VAR_037083"
FT   VARIANT         388
FT                   /note="L -> P (in PC2; dbSNP:rs56690581)"
FT                   /evidence="ECO:0000269|PubMed:16250206"
FT                   /id="VAR_072444"
FT   VARIANT         388
FT                   /note="L -> R (in PC2)"
FT                   /evidence="ECO:0000269|PubMed:23278621"
FT                   /id="VAR_072445"
FT   MUTAGEN         103
FT                   /note="R->A: Down-regulates both proliferation of psoriatic
FT                   T-cells and IFN-gamma production; suppresses keratinocyte
FT                   growth when part of the altered peptide epitope S1."
FT                   /evidence="ECO:0000269|PubMed:16713453"
FT   MUTAGEN         106
FT                   /note="E->A: Down-regulates proliferation of psoriatic
FT                   T-cells and IFN-gamma production when part of the altered
FT                   peptide epitope S1."
FT                   /evidence="ECO:0000269|PubMed:16713453"
FT   MUTAGEN         109
FT                   /note="N->A: No significant effect on T-cell proliferation
FT                   or IFN-gamma production when part of the altered peptide
FT                   epitope S1."
FT                   /evidence="ECO:0000269|PubMed:16713453"
FT   MUTAGEN         154
FT                   /note="N->A: No significant effect on T-cell proliferation
FT                   but reduces IFN-gamma production when part of the altered
FT                   peptide epitope S2."
FT                   /evidence="ECO:0000269|PubMed:16713453"
FT   MUTAGEN         155
FT                   /note="I->A: No significant effect on T-cell proliferation
FT                   but reduces IFN-gamma production when part of the altered
FT                   peptide epitope S2."
FT                   /evidence="ECO:0000269|PubMed:16713453"
FT   MUTAGEN         157
FT                   /note="L->A: Down-regulates proliferation of psoriatic
FT                   T-cells and IFN-gamma production when part of the altered
FT                   peptide epitope S2."
FT                   /evidence="ECO:0000269|PubMed:16713453"
FT   MUTAGEN         160
FT                   /note="D->A: No significant effect on T-cell proliferation
FT                   but reduces IFN-gamma production when part of the altered
FT                   peptide epitope S4."
FT                   /evidence="ECO:0000269|PubMed:16713453"
FT   MUTAGEN         333
FT                   /note="N->A: No significant effect on T-cell proliferation
FT                   but reduces IFN-gamma production when part of the altered
FT                   peptide epitope S4."
FT                   /evidence="ECO:0000269|PubMed:16713453"
FT   MUTAGEN         334
FT                   /note="R->A: No significant effect on T-cell proliferation
FT                   but can induce IFN-gamma production when part of the
FT                   altered peptide epitope S2."
FT                   /evidence="ECO:0000269|PubMed:16713453"
FT   MUTAGEN         336
FT                   /note="C->A: No significant effect on T-cell proliferation
FT                   but reduces IFN-gamma production when part of the altered
FT                   peptide epitope S2."
FT                   /evidence="ECO:0000269|PubMed:16713453"
FT   MUTAGEN         339
FT                   /note="L->A: Down-regulates both proliferation of psoriatic
FT                   T-cells and IFN-gamma production; suppresses keratinocyte
FT                   growth when part of the altered peptide epitope S4."
FT                   /evidence="ECO:0000269|PubMed:16713453"
FT   CONFLICT        30
FT                   /note="R -> Q (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        42
FT                   /note="L -> P (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        51..56
FT                   /note="Missing (in Ref. 3; BAC04534)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        51
FT                   /note="T -> A (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        72
FT                   /note="S -> SS (in Ref. 4; AL353997)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        73..74
FT                   /note="FG -> SFE (in Ref. 4; AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        74
FT                   /note="G -> E (in Ref. 4; AL353997)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        81
FT                   /note="A -> V (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        94..108
FT                   /note="Missing (in Ref. 5; AAH72018)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        137
FT                   /note="T -> I (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        145..147
FT                   /note="ILT -> VGPA (in Ref. 4; AL353997)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        158
FT                   /note="Q -> H (in Ref. 4; AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        159
FT                   /note="I -> N (in Ref. 4; AL353997)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        163
FT                   /note="R -> H (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        167
FT                   /note="D -> A (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        180
FT                   /note="R -> C (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        190..191
FT                   /note="LR -> PC (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        204
FT                   /note="L -> P (in Ref. 4; AL353997)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        207
FT                   /note="Q -> H (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        225
FT                   /note="Missing (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        229
FT                   /note="L -> P (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        242
FT                   /note="D -> G (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        258
FT                   /note="D -> E (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        305
FT                   /note="R -> C (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        337
FT                   /note="V -> M (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        352
FT                   /note="Q -> R (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        357
FT                   /note="R -> L (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        373..375
FT                   /note="VKT -> MKM (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        379
FT                   /note="Q -> L (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        382
FT                   /note="A -> T (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        385
FT                   /note="R -> H (in Ref. 4; AL353997/AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        395..404
FT                   /note="LTQYKKEPVT -> FRMSESSPVS (in Ref. 4; AC022596)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        406
FT                   /note="R -> C (in Ref. 4; AL353997)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        409
FT                   /note="R -> P (in Ref. 4; AL353997)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        428
FT                   /note="H -> R (in Ref. 4; AL353997)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   432 AA;  48106 MW;  35B429243F47EB5C CRC64;
     MTTSIRQFTS SSSIKGSSGL GGGSSRTSCR LSGGLGAGSC RLGSAGGLGS TLGGSSYSSC
     YSFGSGGGYG SSFGGVDGLL AGGEKATMQN LNDRLASYLD KVRALEEANT ELEVKIRDWY
     QRQAPGPARD YSQYYRTIEE LQNKILTATV DNANILLQID NARLAADDFR TKFETEQALR
     LSVEADINGL RRVLDELTLA RADLEMQIEN LKEELAYLKK NHEEEMNALR GQVGGEINVE
     MDAAPGVDLS RILNEMRDQY EKMAEKNRKD AEDWFFSKTE ELNREVATNS ELVQSGKSEI
     SELRRTMQAL EIELQSQLSM KASLEGNLAE TENRYCVQLS QIQGLIGSVE EQLAQLRCEM
     EQQNQEYKIL LDVKTRLEQE IATYRRLLEG EDAHLTQYKK EPVTTRQVRT IVEEVQDGKV
     ISSREQVHQT TR
//
